Evidence map›Paper›PMID 42105344›Full record

ArticleChemistry & biodiversity2026

Tiliroside From Pavonia malacophylla (Link & Otto) Garcke as an Anti-SARS-CoV-2 Cell Entry Agent.

Mariana Freire Campos, Diégina Araújo Fernandes, Janderson Barbosa Leite de Albuquerque, Renata Priscila Barros de Menezes, Maria de Fátima Vanderlei de Souza, Marcus Tullius Scotti, Suzana Guimarães Leitão, Diego Allonso, Gilda Guimarães Leitão

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Chemistry & biodiversity, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Mariana Freire CamposPrograma de Pós-Graduação em Biotecnologia Vegetal e Bioprocessos, Universidade Federal do Rio de Janeiro, Rio de Janeiro, Rio de Janeiro, Brazil.
Diégina Araújo FernandesInstituto de Pesquisas de Produtos Naturais Walter Mors, Universidade Federal do Rio de Janeiro, Rio de Janeiro, Brazil.
Janderson Barbosa Leite de AlbuquerquePrograma De Pós-Graduação em Produtos Naturais e Sintéticos Bioativos, Centro De Ciências da Saúde, Universidade Federal da Paraíba, João Pessoa, Paraíba, Brazil.
Renata Priscila Barros de MenezesPrograma De Pós-Graduação em Produtos Naturais e Sintéticos Bioativos, Centro De Ciências da Saúde, Universidade Federal da Paraíba, João Pessoa, Paraíba, Brazil.
Maria de Fátima Vanderlei de SouzaPrograma De Pós-Graduação em Produtos Naturais e Sintéticos Bioativos, Centro De Ciências da Saúde, Universidade Federal da Paraíba, João Pessoa, Paraíba, Brazil.
Marcus Tullius ScottiPrograma De Pós-Graduação em Produtos Naturais e Sintéticos Bioativos, Centro De Ciências da Saúde, Universidade Federal da Paraíba, João Pessoa, Paraíba, Brazil.
Suzana Guimarães LeitãoDepartamento de Produtos Naturais e Alimentos, Faculdade de Farmácia, Centro de Ciências da Saúde, Universidade Federal do Rio de Janeiro, Rio de Janeiro, Rio de Janeiro, Brazil.
Diego AllonsoDepartamento de Biotecnologia Farmacêutica, Faculdade de Farmácia, Centro de Ciências da Saúde, Universidade Federal do Rio de Janeiro, Rio de Janeiro, Brazil.
Gilda Guimarães LeitãoInstituto de Pesquisas de Produtos Naturais Walter Mors, Universidade Federal do Rio de Janeiro, Rio de Janeiro, Brazil.

Funding

Conselho Nacional de Desenvolvimento Científico e Tecnológico 404646/2023-9Conselho Nacional de Desenvolvimento Científico e Tecnológico 465536/2014-0(Rennofito)Fundação Carlos Chagas Filho de Amparo à Pesquisa do Estado do Rio de Janeiro E-26/201.063/2022Fundação Carlos Chagas Filho de Amparo à Pesquisa do Estado do Rio de Janeiro E-26/211.285/2021
6 · The paper itself

Abstract

Flavonoids are recognized for interfering with stages of SARS-CoV-2 life cycle. Then, tiliroside (kaempferol 3-O-glucoside-6''-E-coumaroyl), an O-glycosylated flavonoid isolated from Pavonia malacophylla (Link & Otto) Garcke, was investigated for its ability to block SARS-CoV-2 viral entry. Tiliroside was chemically characterized and tested for inhibition of the SARS-CoV-2 Spike receptor-binding domain (RBD)-human ACE2 interaction using a bioluminescent immunoassay. At 10 µM, it inhibited 63% of RBD:ACE2 binding. Flow cytometry and pseudovirus assays assessed Spike internalization in endothelial cells and Spike-pseudotyped infection, respectively. Flow cytometry confirmed reduced internalization after tiliroside treatment, while neutralization assays showed a dose-dependent inhibition of pseudovirus infection, with an EC

Indexed as

Antiviral AgentsBetacoronavirusFlavonoidsSARS-CoV-2Virus InternalizationAngiotensin-Converting Enzyme 2AnimalsHumansMolecular Docking SimulationPeptidyl-Dipeptidase ASpike Glycoprotein, CoronavirusACE2 protein, humanAngiotensin-Converting Enzyme 2Antiviral AgentsFlavonoidsPeptidyl-Dipeptidase ASpike Glycoprotein, Coronavirusspike protein, SARS-CoV-2tilirosideantiviral agentsCOVID‐19glycoproteinskaempferol 3‐O‐glucoside‐6”‐E‐coumaroylMalvaceaeO‐glycosylated flavonoids

Identifiers

PMID42105344
PMCPMC13376688

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.